Knee osteoarthritis: disease burden, available treatments, and emerging options
- PMID: 39290780
- PMCID: PMC11406648
- DOI: 10.1177/1759720X241273009
Knee osteoarthritis: disease burden, available treatments, and emerging options
Abstract
Osteoarthritis (OA) is a prevalent condition that affects nearly 528 million people worldwide, including 23% of the global population aged ⩾40, and is characterized by progressive damage to articular cartilage, which often leads to substantial pain, stiffness, and reduced mobility for affected patients. Pain related to OA is a barrier to maintaining physical activity and a leading cause of disability, accounting for 2.4% of all years lived with disability globally, reducing the ability to work in 66% of US patients with OA and increasing absenteeism in 21% of US patients with OA. The joint most commonly involved in OA is the knee, which is affected in about 60%-85% of all OA cases. The aging population and longer life expectancy, coupled with earlier and younger diagnoses, translate into a growing cohort of symptomatic patients in need of alternatives to surgery. Despite the large number of patients with knee OA (OAK) worldwide, the high degree of variability in patient presentation can lead to challenges in diagnosis and treatment. Multiple society guidelines recommend therapies for OAK, but departures from guidelines by healthcare professionals in clinical settings reflect a discordance between evidence-based treatment algorithms and routine clinical practice. Furthermore, disease-modifying pharmacotherapies are limited, and treatment for OAK often focuses solely on symptom relief, rather than underlying causes. In this narrative review, we summarize the patient journey, analyze current disease burden and nonsurgical therapy recommendations for OAK, and highlight emerging and promising therapies-such as cryoneurolysis, long-acting corticosteroids, and gene therapies-for this debilitating condition.
Keywords: NSAIDs; emerging therapies; guidelines; intraarticular injections; osteoarthritis.
© The Author(s), 2024.
Conflict of interest statement
M.L. has served as a consultant for Pacira BioSciences, Inc., and receives royalties from Orthodevelopment. V.D. has served as a consultant or speaker for, received research support from, and/or has stock in Bioventus (specifically regarding DUROLANE), Emovi, Ferring, Goldfinch Consulting, Grand Care, J. Robert Gladden Orthopaedic Society, Medi Post, MEND, Motive, My Medical Images, Pacira BioSciences, Inc. (specifically regarding EXPAREL, iovera°, and ZILRETTA), Sanofi (specifically regarding SYNVISC), SIGHT Medical, STRIVE MedTech, the Journal of Orthopaedic Experience & Innovation, the National Institutes of Health, the Orthopaedic Research and Education Foundation, and Vertex. A.I.S. has served as a consultant, speaker, and/or researcher for DePuy, Pacira BioSciences, Inc. (specifically regarding ZILRETTA), and TraumaCad (Brainlab).
Figures
References
-
- American Academy of Orthopaedic Surgeons. Management of osteoarthritis of the knee (nonarthroplasty) evidence-based clinical practice guideline, https://www.aaos.org/oak3cpg (2021, accessed 24 April 2024).
-
- Whittaker JL, Runhaar J, Bierma-Zeinstra S, et al. A lifespan approach to osteoarthritis prevention. Osteoarthritis Cartilage 2021; 29: 1638–1653. - PubMed
-
- Grassel S, Muschter D. Recent advances in the treatment of osteoarthritis. F1000Research 2020; 9: F1000 Faculty Rev-1325.
-
- Sakalauskiene G, Jauniskiene D. Osteoarthritis: etiology, epidemiology, impact on the individual and society and the main principles of management. Medicina (Kaunas) 2010; 46: 790–797. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
